Clinical Trials · global
BioNTech Breast Cancer ADC Meets Phase 3 Endpoint, but Limited Efficacy and Fatal Lung Events Cloud Outlook
The results for delaying disease progression met the statistical threshold, yet did not prompt an optimistic assessment from the developers. Increased lung toxicity and immature survival data for trastuzumab pamirtecan highlight the benefit–risk threshold new breast cancer therapies must clear.
For patients with metastatic breast cancer, whether a new drug can provide more time with their disease under control must be weighed alongside the costs of treatment. BioNTech and DualityBio announced on October 26 that their jointly developed trastuzumab pamirtecan met the primary endpoint in a Phase 3 breast cancer trial. However, both companies stated plainly that the improvement was modest and that patients may derive limited benefit in the current treatment landscape.
The global trial, called DYNASTY-Breast02, enrolled 541 patients with hormone receptor-positive, HER2-low metastatic breast cancer whose disease had progressed after endocrine therapy and who had not received chemotherapy for metastatic disease. Patients were randomly assigned to receive either the investigational drug or a single chemotherapy agent chosen by their physician.
Trastuzumab pamirtecan, also known as BNT323/DB-1303, is a HER2-targeting antibody-drug conjugate (ADC) that combines an antibody recognizing a protein on the tumor surface with a cytotoxic drug. HER2-low means that tumors still have detectable HER2 protein, but at lower levels, providing a target for this type of drug.
The trial showed that the drug was superior to chemotherapy in progression-free survival, with a statistically significant difference. This measure tracks how long patients remain alive without their disease worsening. However, the announcement did not provide median times for the two groups, a hazard ratio, or full statistical data, making it impossible at this stage to quantify how much additional time was gained. Overall survival data are also immature, and whether the drug can extend life remains unresolved.
Safety further complicates the results. The companies said the incidence of interstitial lung disease in this trial was higher than in previous trials of the drug. Most cases were Grade 1 or 2, but a small proportion of patients experienced severe or fatal Grade 3–5 events. The announcement did not provide exact patient counts or percentages for each grade, making it difficult to fully assess the magnitude of the lung risk.
BioPharma Dive's report on the same day also confirmed these efficacy and safety signals and interpreted the results within the competitive landscape established by Enhertu. Developed by AstraZeneca and Daiichi Sankyo, Enhertu is also a HER2-targeting ADC and has entered use in HER2-low breast cancer treatment. However, the control arm in DYNASTY-Breast02 received chemotherapy, rather than Enhertu, so these results cannot support a direct comparison of the two drugs' relative merits.
The two companies said they would discuss the data and determine next steps, but have not announced the future direction of this breast cancer development program. The central question left by these results is whether a modest improvement in disease control can outweigh the cost of lung injury. Full efficacy and safety data, along with further survival follow-up, are needed to make that judgment clearer.